DMK Pharmaceuticals Commences Restructuring Proceeding Feb 2, 2024 08:28PM
DMK Pharmaceuticals (DMK) Regains Full Rights to Commercialize ZIMHI Dec 21, 2023 08:15AM
DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI Dec 21, 2023 08:15AM
DMK Pharmaceuticals (DMK) Regains Full Rights from US WorldMeds for SYMJEPI and Provides Corporate Update Nov 28, 2023 08:05AM
DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update Nov 28, 2023 08:05AM


Nov 14, 2023 07:30AM DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Nov 13, 2023 10:53AM DMK Pharmaceuticals (DMK) Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care
Nov 13, 2023 10:52AM DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023
Oct 19, 2023 04:06PM DMK Pharmaceuticals (DMK) Restructures Executive Team
Oct 19, 2023 04:05PM DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth
Sep 7, 2023 12:00PM Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus